Therapeutic CD154 antibody for lupus: promise for the future?
1Department of Immunology, Duke University, Durham, North Carolina 27710, USA. ghkelsoe@duke.edu
The Journal of Clinical Investigation
|November 18, 2003
Abstract:
Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease characterized by the production of pathogenic autoantibodies. A new study demonstrates that passive antibody specific for the TNF family member, CD154, ameliorates disease by reducing levels of self-reactive antibody in the serum. This study demonstrates a substantial potential for anti-CD154 antibody in the treatment of humoral autoimmunity.
